Wedbush is removing Argenx (ARGX) from the firm’s Best Ideas List. Wedbush remains constructive on the name, but believes the upside isn’t compelling enough to warrant inclusion on the BIL.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx: Strong Market Position and Growth Potential Justify Buy Rating
- Argenx price target raised to $925 from $830 at JPMorgan
- Promising Outlook for arGEN X: Robust Sales Projections and Strategic Expansion Drive Positive Risk-Reward Balance
- Denali says chief medical officer Carole Ho to depart to join Eli Lilly
- Argenx announces Health Canada approval of Vyvgart in CIDP